Research progress on tuberculosis patients treatment adherence: current status, influencing factors, and intervention measures

doi:10.19983/j.issn.2096-8493.20230076

Abstract

Abstract:

Anti-tuberculosis (TB) treatment requires long-term, regulated administration of multiple drugs, which can easily lead to non-adherence during treatment and affect treatment outcomes. This article aims to review the current status, influencing factors and intervention measures of treatment adherence of TB patients, and provide reference for improving treatment adherence among TB cases.

Key words: Tuberculosis, Deinstitutionalization, Patient compliance, Epidemiologic factors, Intervention studies, Review literature as topic

CLC Number:

R52
R184

Ruan Shujin, Zeng Jian, Chen Jingfang, Wang Xiufen, Liu Linlin, Jiang Youli, Li Mengjun. Research progress on tuberculosis patients treatment adherence: current status, influencing factors, and intervention measures[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(5): 419-424. doi: 10.19983/j.issn.2096-8493.20230076

References 54

[1]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	Chimeh RA, Gafar F, Pradipta IS, et al. Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic review. Int J Tuberc Lung Dis, 2020, 24(8):811-819. doi:10.5588/ijtld.19.0754. pmid: 32912386
[3]	Garcia-Cremades M, Solans BP, Strydom N, et al. Emerging Therapeutics, Technologies, and Drug Development Strategies to Address Patient Nonadherence and Improve Tuberculosis Treatment. Annu Rev Pharmacol Toxicol, 2022, 62:197-210. doi:10.1146/annurev-pharmtox-041921-074800.
[4]	Kwon SH, Nam JH, Kim HL, et al. Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data. Front Pharmacol, 2022, 13:918344. doi:10.3389/fphar.2022.918344.
[5]	Liu X, Thompson J, Dong H, et al. Digital adherence technologies to improve tuberculosis treatment outcomes: A cluster-randomised superiority trial. Lancet Glob Health, 2023, 11(5): e693-e703. doi:10.1016/S2214-109X(23)00068-2.
[6]	丰达星, 张璐, 吕宛玉, 等. 我国耐多药结核患者治疗依从性影响因素meta分析. 实用预防医学, 2019, 26(7):823-826. doi:10.3969/j.issn.1006-3110.2019.07.014.
[7]	中华人民共和国卫生部疾病预防控制局, 中华人民共和国卫生部医政司, 中国疾病预防控制中心. 中国结核病防治规划实施工作指南(2008年版). 北京: 中国协和医科大学出版社, 2009.
[8]	李明虎, 孙谨芳. 耐多药结核病患者治疗管理依从性影响因素分析. 中国防痨杂志, 2009, 31(10):617-618.
[9]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: tuberculosis care and support. Geneva: World Health Organization, 2022.
[10]	Zhang M, Wang G, Najmi H, et al. Digitizing tuberculosis treatment monitoring in Wuhan city, China, 2020—2021: Impact on medication adherence. Front Public Health, 2023, 11:1033532. doi:10.3389/fpubh.2023.1033532.
[11]	Lei X, Huang K, Liu Q, et al. Are tuberculosis patients adherent to prescribed treatments in China? Results of a prospective cohort study. Infect Dis Poverty, 2016, 5:38. doi:10.1186/s40249-016-0134-9. pmid: 27146470
[12]	Wang X, Fu Q, Zhou M, et al. How Integrated Digital Tools Can Improve Tuberculosis Medication Adherence: A Longitudinal Study in China. Telemed J E Health, 2023. doi:10.1089/tmj.2023.0084.
[13]	Nellums LB, Rustage K, Hargreaves S, et al. Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis. BMC Med, 2018, 16(1):27. doi:10.1186/s12916-017-1001-7. pmid: 29466983
[14]	de Groot LM, Straetemans M, Maraba N, et al. Time Trend Analysis of Tuberculosis Treatment While Using Digital Adherence Technologies-An Individual Patient Data Meta-Analysis of Eleven Projects across Ten High Tuberculosis-Burden Countries. Trop Med Infect Dis, 2022, 7(5):65. doi:10.3390/tropicalmed7050065.
[15]	龚新记, 文进, 李月华, 等. 3071例成人新登记涂阳肺结核患者治疗结局分析. 新疆医科大学学报, 2020, 43(11):1514-1517. doi:10.3639/j.issn.1009-5551.2020.11.025.
[16]	Zhdanov V, Bilenko N, Mor Z. Risk Factors for Recurrent Tuberculosis among Successfully Treated Patients in Israel, 1999—2011. Isr Med Assoc J, 2017, 19(4):237-241.
[17]	王硕, 何梦雅, 张艳秋, 等. 1165例耐多药和广泛耐药肺结核患者治疗结局及影响因素分析. 疾病监测, 2023, 38:1-9. doi:10.3784/jbjc.202303170106.
[18]	袁燕莉, 于宝柱, 姜世闻, 等. 肺结核患者治疗依从性评分系统的研究. 北京大学学报(医学版), 2010, 42(3):299-303. doi:10.3969/j.issn.1671-167X.2010.03.012.
[19]	陈玮. 贵州省肺结核患者治疗依从性评分系统应用研究. 重庆:第三军医大学, 2016.
[20]	王春雷, 金韬, 赵鹏鹏, 等. 江苏省淮安市耐多药肺结核患者服药依从性及影响因素分析. 中国防痨杂志, 2022, 44(10):1057-1062. doi:10.19982/j.issn.1000-6621.20220214.
[21]	World Health Organization. Adherence to long-termtherapies:evidence for action. Geneva: World Health Organization, 2003.
[22]	梁汝江, 井明霞, 张梅, 等. 社区管理高血压患者的服药依从性预测模型构建. 石河子大学学报(自然科学版), 2021, 39(1):121-125. doi:10.13880/j.cnki.65-1174/n.2020.22.043.
[23]	张素娟, 韩彦周, 李华, 等. 初治涂阳肺结核患者抗结核治疗不良反应发生现状及影响因素分析. 河北医科大学学报, 2021, 42(5):536-540. doi:10.3969/j.issn.1007-3205.2021.05.009.
[24]	余雅, 廖文平, 刘英, 等. 重庆市贫困区(县)肺结核患者的治疗依从性及其影响因素研究. 疾病监测, 2021, 36(11):1159-1167. doi:10.3784.jbjc.202105060233.
[25]	尤媛媛, 张国龙, 陈裕. 120例初治耐多药肺结核患者治疗依从性的影响因素分析. 中国防痨杂志, 2020, 42(3):249-254. doi:10.3969/j.issn.1000-6621.2020.03.013.
[26]	Nezenega ZS, Perimal-Lewis L, Maeder AJ. Factors Influencing Patient Adherence to Tuberculosis Treatment in Ethiopia: A Literature Review. Int J Environ Res Public Health, 2020, 17(15):5626. doi:10.3390/ijerph17155626.
[27]	周倩茹, 王玲华. 耐多药结核病患者抑郁倾向相关因素研究进展. 中国防痨杂志, 2022, 44(2):197-202. doi:10.19982/j.issn.1000-6621.20210411.
[28]	敖建, 吴婧, 胡典贵, 等. 结核病合并艾滋病感染患者抗结核治疗依从性及其影响因素分析. 中国当代医药, 2021, 28(5):46-48.
[29]	汪敏, 袁园, 谭守勇, 等. 2型糖尿病合并初治菌阳肺结核患者肺部广泛病灶和空洞发生的危险因素分析. 中国防痨杂志, 2023, 45(8):761-767. doi:10.19982/j.issn.1000-6621.20230147.
[30]	顾宇人, 唐佩军. 抗结核药物性肝损伤相关危险因素研究进展. 结核与肺部疾病杂志, 2021, 2(3):283-288. doi:10.3969/j.issn.2096-8493.20210055.
[31]	蒋博峰, 马晨晨, 陈阳贵, 等. 抗结核药物不良反应发生率及其影响因素分析. 中华疾病控制杂志, 2017, 21(2):160-163. doi:10.16462/j.cnki.zhjbkz.2017.02.013.
[32]	Ajema D, Shibru T, Endalew T, et al. Level of and associated factors for non-adherence to anti-tuberculosis treatment among tuberculosis patients in Gamo Gofa zone, southern Ethiopia: cross-sectional study. BMC public health, 2020, 20(1):1705. doi:10.1186/s12889-020-09827-7. pmid: 33187496
[33]	陈双双, 沙巍, 刘晓宁, 等. 首次复治肺结核患者采用短程化疗方案的疗效评价. 中国防痨杂志, 2021, 43(11):1153-1158. doi:10.3969/j.issn1000-6621.2021.11.009.
[34]	胡远莲, 邓玲, 艾萍, 等. 肺结核患者社区治疗管理调查分析. 中国防痨杂志, 2022, 44(5):473-477. doi:10.19982/j.issn.1000-6621.20210637.
[35]	Chen X, Du L, Wu R, et al. The effects of family, society and national policy support on treatment adherence among newly diagnosed tuberculosis patients: a cross-sectional study. BMC Infect Dis, 2020, 20(1):623. doi:10.1186/s12879-020-05354-3. pmid: 32831050
[36]	王泊宁, 李涛, 陈伟. 耐药结核病经济负担研究进展. 中国防痨杂志, 2023, 45(6):607-612. doi:10.19982/j.issn.1000-6621.20230018.
[37]	吴颖, 杜桂春, 鲍丙丽, 等. 初治涂阳肺结核患者心理学特征及支持性心理干预后的效果分析. 结核病与肺部健康杂志, 2019, 8(1):48-53. doi:10.3969/j.issn.2095-3755.2019.01.012.
[38]	李珍, 常立阳, 王玲华. 肺结核患者健康教育在临床实践中的实施现状与思考. 中国防痨杂志, 2021, 43(11):1132-1138. doi:10.3969/j.issn1000-6621.2021.11.006.
[39]	陈晓凤, 彭乐, 刘继星, 等. 专职健康教育护士对住院结核病患者的干预效果分析. 中国防痨杂志, 2020, 42(10):1109-1114. doi:10.3969/j.issn1000-6621.2020.10.017.
[40]	邢伟. 重庆市耐多药结核病(MDR-TB)患者治疗依从性、管理现状及影响因素研究. 重庆:中国人民解放军陆军军医大学, 2021.
[41]	Ni N, Wang N, Veronese V, et al. Current status and future prospects of TB digital treatment adherence technology use in China. Int J Tuberc Lung Dis, 2023, 27(6):438-443. doi:10.3390/ijerph17155626. pmid: 37231604
[42]	Liu X, Thompson J, Dong H, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health, 2023, 11(5):e693-e703. doi:10.1016/S2214-109X(23)00068-2.
[43]	Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med, 2021, 384(18):1705-1718. doi:10.1056/NEJMoa2033400.
[44]	World Health Organization. Consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, 2022. Geneva: World Health Organization, 2022.
[45]	周奉, 李同心, 杨松, 等. 结核病短程治疗方案的研究进展. 中国防痨杂志, 2023, 45(3):311-317. doi:10.19982/j.issn.1000-6621.20220447.
[46]	叶江娥, 王静秋, 王舰, 等. 患者关爱与支持管理模式对结核病患者自律性和自我效能的影响. 结核与肺部疾病杂志, 2023, 4(3):216-222. doi:10.19983/j.issn.2096-8493.20230046.
[47]	胡雪丹. 多学科团队协作护理干预在耐药肺结核患者自我管理中的应用研究. 南昌:南昌大学, 2021.
[48]	张铁娟, 潘艳, 马建军, 等. 医疗保险支付新模式减轻肺结核患者经济负担的效果分析. 中国防痨杂志, 2021, 43(8):778-782. doi:10.3969/j.issn.1000-6621.2021.08.005.
[49]	Jiang WX, Long Q, Lucas H, et al. Impact of an innovative financing and payment model on tuberculosis patients’ financial burden: is tuberculosis care more affordable for the poor? Infect Dis Poverty, 2019, 8(1):21. doi:10.1186/s40249-019-0532-x.
[50]	余美玲, 梁鸿迪, 周芳静, 等. 广东省耐多药结核病灾难性支出发生情况及其影响因素分析. 中国防痨杂志, 2022, 44(12):1262-1272. doi:10.19982/j.issn.1000-6621.20220235.
[51]	张岚, 郭强, 马玉宝, 等. 甘肃省回族地区结核病健康扶贫重点指标监测分析. 疾病监测, 2021, 36(11):1129-1132. doi:10.3784/jbjc.202106150338.
[52]	胡娟, 周燕, 杨澄清. 支气管结核患者焦虑、抑郁心理状况与行电子支气管镜治疗依从性的相关性分析. 结核与肺部疾病杂志, 2022, 3(4):305-308. doi:10.19983/j.issn.2096-8493.20220090.
[53]	赵阿利, 袁荣, 罗卉, 等. 以患者为中心的耐多药/利福平耐药结核病患者关怀服务实施效果分析. 中国防痨杂志, 2021, 43(6):606-611. doi:10.3969/j.issn.1000-6621.2021.06.015.
[54]	Farooq S, Tunmore J, Comber R. Pharmacological or non-pharmacological interventions for treatment of common mental disorders associated with tuberculosis: A systematic review. Chron Respir Dis, 2021, 18:241539039. doi:10.1177/14799731211003937.